The study evaluates the influence of monocytes/macrophages in the mechanisms of skeletal muscle injury using a mouse model and selective depletion of peripheral monocyte with systemic injections of liposomal clodronate (dichloromethylene bisphosphonate). This pharmacological treatment has been demonstrated to induce specific apoptotic death in monocytes and phagocytic macrophages. In the current studies, the liposomal clodronate injections resulted in a marked attenuation of the peak inflammatory response in the freeze-injured muscle in the first three days after injury. prolonged clearance of necrotic myofibers and a tendency for increased muscle fat accumulation at day 9 and 14 post injury, respectively. In conclusion, a significant reduction of the initial monocyte/macrophage influx into the injured muscle is associated with not improved but moderately impaired repair processes following skeletal muscle injury.
INTRODUCTION
Inflammation is an obligatory event in skeletal muscle injury resulting from a variety of mechanisms, including crush, freezing, overuse, chemical, and biological insults (32) . Recovery of skeletal muscle injuries requires severely injured myofibers to be degraded, phagocytized, and replaced via the migration and maturation of satellite cells. It is well established that after a brief initial neutrophil influx into the muscle, macrophages become the dominant inflammatory cell type by ~1 day and with peak levels at day 3 post-injury (17, 34, 37) . Several studies have reported that macrophages can promote both degeneration and regeneration of muscle cells, though the likelihood of this dual role after in vivo muscle injury remains controversial (33) . Macrophages are involved in phagocytosis and removal of cellular debris derived from necrotic muscle tissue (16, 17) . It has also been shown that macrophages isolated from dystrophic muscles of mdx mice are highly cytotoxic for muscle cells (40). In contrast, increasing in vitro evidence has demonstrated that macrophages can enhance the replication and differentiation of muscle precursor cells (3, 10, 13, 25) . It is possible that all phases of muscle injury including degeneration, regeneration, and fibrosis are influenced by mediators released from activated macrophages including inflammatory cytokines, chemokines, and growth factors (8, 33) . Consistent with a role of macrophages in regenerative mechanisms are the in vivo observations that recovery of muscle function post-injury begins at approximately the time of peak macrophage infiltration (12, 38, 39) .
Furthermore, increasing data suggest that resident macrophages and macrophages originating from the systemic circulation as well as phagocytic and non-phagocytic macrophages may play different roles during muscle injury (11, 14, 29, 33) .
Modulating, either by reducing or enhancing, the influx of macrophages into injured muscle tissue is an attractive target for therapeutic interventions. However, the role of this influx in controlling the outcome of muscle injury is not well understood.
Systemic injections of liposome-encapsulated clodronate (dichloromethylene bisphosphonate) in mice have been demonstrated to deplete rapidly (within 24 hours) 90% of the peripheral monocytes as well as tissue macrophages which are achieved with the liposomes (31, 36). The treatment has been shown to induce selective apoptotic cell death in monocytes/macrophages without affecting lymphocytes and neutrophils (23, 36) .
Furthermore, unlike other methods of macrophage depletion, the clodronate-mediated anti-monocyte/macrophage approach does not result in secretion of pro-inflammatory cytokines (35). Although, liposomal clodronate has been applied to study the role of monocytes/macrophages in a variety of disease and injury models, its effects in skeletal muscle disorders have not been studied. The objective of our study was to gain better insight into the role of inflammatory cell influx in muscle injury and repair using the liposomal clodronate pharmacological method for peripheral monocytes/macrophages depletion. We hypothesized that minimizing the monocyte/macrophage response to trauma would modulate the muscle's ability to recover from traumatic injury. To test the hypothesis, liposomes loaded with clodronate or phosphate-buffered saline (PBS) (as a control) were injected into mice both before and after induction of a freeze injury to the tibialis anterior (TA) muscle. The injury/repair process was evaluated by histopathological assessment as well as by quantifying the expression of genes involved in the initial events after injury.
METHODS
Animals. C57BL/6 female wild-type mice (The Jackson Laboratory, Bar Harbor, ME) were provided food and water ad libitum and maintained on a 12-hr light/dark cycle.
In preparation for muscle injury induction, mice were anesthetized with 0.33 mg/kg fentanyl, 16.7 mg/kg droperidol, and 5.0 mg/kg diazepam administered intraperitoneally (ip). Animal care and use procedures, including death by CO 2 asphyxiation, were conducted in accordance with criteria outlined in the "PHS Policy on Humane Care and Use of Laboratory Animals" and the "Guide for the Care and Use of Laboratory Animals" (NIH publication 1996) ; these procedures were approved by the NIOSH institutional animal care and use committee.
Injection of liposomes.
Clodronate-and PBS-loaded liposomes were prepared as described earlier (36) . Clodronate was a gift of Roche Diagnostics GmbH, Mannheim, Germany. Mice were injected with clodronate-liposomes or PBS-liposomes 2 days (0.2 ml of liposomes administered intravenously, i.v., through the tail vein) and 2 hours (0.1 ml of liposomes administered i.p.) prior to muscle injury. Additionally, in the 9 and 14 days post injury studies, liposomes (clodronate-or PBS-, respectively) (0.1 ml, i.p.) were continued to be administered every third day after the injury. This protocol was based on previous publications (21) as well as discussions through the web site of the ClodronateLiposomes.org. To evaluate the effects of clodronate-liposome treatment on peripheral leukocytes, blood smears were prepared from the foot vein for all of the experimental animals; the smears were stained with the Wright stain; 100 cells per slide and two slides per animal were counted. There was no difference, measurable by this method, in the leukocyte counts between the two treatments at any time point (the average count was: % lymphocytes 87+ 5; % neutrophils 12+ 5; %monocytes <2).
Induction of muscle injury. The muscle injury induction procedure was identical to that described previously (37) . In brief, a 1.5-cm-long incision was made through aseptically-prepared skin overlying the left TA muscle belly. Injury was induced by applying a steel probe cooled to the temperature of dry ice to the TA muscle belly for 10 s. This injury results in approximately 60% damage of the TA, influx of inflammatory cells mainly monocytes/macrophages as well as activation of the regeneration in the first 3 days after injury, and recovery of the histopathology by 14 days after injury (37) . cross-sections (10-µm thick) were cut at each of six levels equally spaced along the length of the TA muscle. Sections at each level were used for routine hematoxylin-eosin (H&E) staining or for immunohistology. Myofiber cross-sectional areas (CSA) in regenerating muscles at 9 days post-injury were determined using H&E-stained sections as described before (38) . Briefly, the average uninjured and regenerating myofiber areas were determined for each muscle. Sections chosen for analysis were ones: 1) with the highest fraction of the muscle area showing injury/regeneration and 2) a well-demarcated border between the regions of regenerating and uninjured myofibers; only fibers in the vicinity of the border were analyzed. Regenerating myofibers chosen for analysis were centronucleated fibers not bordering a fiber that was not centronucleated. Likewise, uninjured myofibers chosen for analysis were non-centronucleated fibers that did not border a centronucleated fiber. Between 190 and 255 myofibers were analyzed per muscle. For each muscle, the average uninjured and regenerating myofiber areas were determined using at least 5 mice per group. Measurements were performed using a Leica Leitz DMRB microscope, 20x objective, and MediaCybernetics Optimas 6.5 software (Media Cybernics, Silver Spring, MD). Muscles processed for longitudinal-section histology were fixed by immersion in 10% neutral-buffered formalin. Masson's trichrome stain to visualize collagen was applied as described originally (27) . and blue thresholds to estimate the stained areas, the Optimas software measured the total area, stained area, and percent stained area. The same thresholds and lighting conditions were used for all sections for a given stain.
Immunostainings for MyoD, marker of muscle precursor cell activation/proliferation, was performed on formalin-fixed cross-cryosections using polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) as described previously (37) . Control experiments omitting the primary antibodies were used for demonstrating specificity of the immunostaining. Statistics. The expression of each gene was obtained from 5 animals per group and triplicate measures. Differences in mRNA transcript levels between the two treatments were analyzed using unpaired t-tests or Mann-Whitney tests when assumptions of normality or equal variance were violated; Bonferroni adjustments were applied to control for Type I error inflation due to the multiple comparisons.
Real Time RT-PCR. Muscles were collected in
For comparison of myofiber CSAs between the two groups of mice, first an average CSA for each type myofibers (regenerating or uninjured) in each muscle was calculated. These averaged CSA values were then analyzed using the 2-way (group x myofiber type) repeated measures ANOVA. For immunostaining comparison, the percent stained area was averaged for each muscle and analyzed by ANOVA single factor.
RESULTS

Monocyte/macrophage depletion
To evaluate the depleting effects of clodronate-liposome treatment in injured muscle, the muscle was assessed by mRNA expression for Mac-1 (integrin beta 2 subunit, CD18 beta subunit), a marker of leukocytes including monocytes/macrophages and neutrophils ( 3). At 9 days post-injury, the damaged muscle area in the PBS-liposome treated mice had been replaced mostly by centronucleated myofibers (indicating regenerating myofibers), whereas numerous necrotic myofibers and inflammatory cells dominated the injured muscle regions of clodronate-liposome treated mice (Fig. 3B) . However, the mean regenerating myofiber CSA was not different between PBS-liposome and clodronate-liposome treated mice at 9 days post-injury (0.53+0.09 and 0.527+ 0.053, respectively). Two weeks after injury, no sign of damage was detectable in the PBSliposome treated muscles. The histopathology at this time point was comparable for the mice treated with clodronate-liposomes except increased fat infiltration (severity grade of 3 for 5 and 2 for 2 mice) into the interstitium of the injured TA muscle (Fig. 3D ).
Collagen staining was minimal in the regenerating muscles from both treatment groups (representative images Fig. 3D ). Furthermore, immunohistochemistry for a vascular endothelial cell marker, CD31/PECAM-1 (19), was conducted to assess whether angiogenesis was altered in regenerating muscle of clodronate-treated mice. We observed no differences in the number of CD31-positive cells between the PBS-and clodronate-liposome treated groups (representative images Fig. 3C ). However, we cannot rule out the possibility that small differences in the number or diameter of microvessels may exist between the treatment groups. Morphometric analysis using quantitative stereology confirmed that at 9 days after injury the percent of the necrotic myofebers as well as the interstitial inflammation was significantly higher in the clodronate-treated mice compared to the PBS-control treated group (Fig. 3E) .
Furthermore, this analysis confirmed that at 14 days the interstitial fat accumulation was significantly higher in the clodronate-treated group compared to the PBS-control treated group (Fig. 3E) .
Effect of monocyte/macrophage depletion on expression of genes coding for mediators related to muscle injury/repair
Real-time RT-PCR was applied to evaluate whether the macrophage influx into the injured muscle affects the expression of genes associated with initial stages of the muscle injury/repair process. As we have demonstrated before, using mainly DNA microarray gene expression analysis, the expression of genes coding for mediators related to inflammation, oxidative stress, or cell growth, including TNFα, MCP-1, thioredoxin, HMGA, IGFBP, IGF-1, CSF-1, and TGFβ, is up-regulated in TA muscle at the first days post freeze injury (30) . The clodronate-liposome treatment did not modify the mRNA transcript levels in the control (uninjured) muscles for all of the genes of interest. In contrast, this treatment significantly reduced injury-induced mRNA transcripts of TNFα, MCP-1, thioredoxin, HMGA, and IGFBP at 1 day post-injury (Fig 4A-C) . Of these five genes, only TNFα mRNA expression continued to show a statistically significant decrease at 3 days post-injury (Fig 4A) . Furthermore, at day 3 post-injury, injured muscles from clodronate-liposome treated mice also expressed less IGF-1 mRNA compared to injured muscles from PBS-liposome treated mice (Fig. 4C) . In contrast,
CSF-1 as well as TGFβ gene expression was not affected by the monocyte/macrophage depletion at either 1 or 3 days post-injury (data not shown).
To evaluate the effect of clodronate-liposome treatment on the maturation of muscle precursor cells, real-time RT-PCR was applied to determine the expression of MyoD and myogenin, markers of activated/proliferating and differentiating muscle precursor cells, respectively (26) . When compared to uninjured control muscles, increases in MyoD and myogenin expression occurred in the injured muscles of both the PBS-and clodronate-liposome treated mice at 3 days post-injury (p< 0.05) (Fig. 5) .
However, the transcript levels of these myogenic factors in the injured muscle did not differ between the two treatment groups. Consistent with the MyoD RT-PCR data, MyoD-immunostained nuclei, which belonged to activated and proliferating myoblasts, were found by day 3 post-injury in the injured muscles of both PBS-and clodronateliposome treated groups (Fig. 6 ).
DISCUSSION
The clodronate-liposome treatment, which targets mainly peripheral monocytes/macrophages, results in a marked attenuation of the peak inflammatory response in the injured muscle in the first three days after injury. This effect is accompanied with a transient reduction of the expression of genes coding for mediators that may affect a variety of cells involved in the injury/repair process of the muscle.
However, the expression of major myogenic factors (i.e., MyoD and myogenin), directly involved in the activation/proliferation and differentiation of muscle precursor cells, is not altered by the clodronate-liposome treatment. Under these circumstances, the injured muscle regenerates but the repair process is impaired by prolonged clearance of necrotic myofibers and a tendency for increased muscle fat accumulation.
Growing evidence demonstrates that monocytes/macrophages (hematogenous or resident) are involved in wound-healing mechanisms, including those from muscle injury (for review, see (33) . Many physiological processes such as aging, hypoperfusion, and local or systemic infection likely exert some of their negative effects on muscle regeneration secondary to suppression of the innate immune system (e.g., inflammatory cell activation). The strongest evidence that impaired inflammatory responses are detrimental to muscle regeneration has arisen from the numerous studies investigating the use of anti-inflammatory drugs (e.g., corticosteroids and non-steroidal anti-inflammatory drugs) after muscle injury (for review, see (1, 22) . These drugs may be mildly beneficial 
